@article{acd3a5cac971410888761e3aecf2f0f5,
title = "Pharmacological characterization of a novel putative nootropic beta-alanine derivative, MB-005, in adult zebrafish",
abstract = "Background: Cognitive deficits represent an urgent biomedical problem, and are commonly reduced by nootropic drugs. Animal models, including both rodents and zebrafish, offer a valuable tool for studying cognitive phenotypes and screening novel nootropics. Beta-alanine and its derivatives have recently been proposed to exert nootropic activity.Aims: This study aimed to characterize putative nootropic profile of a novel beta-alanine analogue, 1,3-diaminopropane (MB-005), in adult zebrafish.Methods: Nootropic profile of MB-005 was assessed in adult zebrafish in the novel tank and conditioned place aversion (CPA) tests acutely, and in cued-learning plus-maze (PMT) tests chronically.Results/Outcomes: MB-005 did not atter zebrafish anxiety-like behavior or monoamine neurochemistry acutely, improved short-term memory in the CPA test, but impaired cognitive performance in both CPA and PMT tests chronically.Conclusions/Interpretation: This study reveals high sensitivity of zebrafish cognitive phenotypes to MB-005, suggesting it as a potential novel cognitive enhancer acutely, but raises concerns over its cognitive (and, possibly, other) side-effects chronically.",
keywords = "Nootropics, zebrafish, memory, piracetam, beta-alanine, INDUCED MEMORY IMPAIRMENT, COGNITIVE DEFICITS, GABA(C) RECEPTORS, PIRACETAM, DRUGS, MODELS, BENZODIAZEPINES, EFFICACY, SUPPLEMENTATION, PERFORMANCE",
author = "T.O. Kolesnikova and D.S. Galstyan and K.A. Demin and M.A. Barabanov and A.V. Pestov and {de Abreu}, M.S. and T. Strekalova and A.V. Kalueff",
note = "Funding Information: AVK is the Chair of the International Zebrafish Neuroscience Research Consortium (ZNRC) and President of the International Stress and Behavior Society (ISBS, www.stress-and-behavior.com) who coordinated this collaborative multilaboratory project. The consortium provided a collaborative idea exchange platform for this study, it is not considered as affiliation and did not fund the study. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by the Sirius University of Science and Technology (Project: ID NRB-RND-2116). AVK is supported by St. Petersburg State University funds (Project ID 93020614). The study also used the facilities and equipment of the Resource Fund of Applied Genetics MIPT (support grant 075-15-2021-684). The authors thank Prof. R.R. Gainetdivov (Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia) for his generous assistance with the HPLC studies. The funders had no role in the design, analyses, and interpretation of the submitted study, or decision to publish. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by the Sirius University of Science and Technology (Project: ID NRB-RND-2116). AVK is supported by St. Petersburg State University funds (Project ID 93020614). The study also used the facilities and equipment of the Resource Fund of Applied Genetics MIPT (support grant 075-15-2021-684). The authors thank Prof. R.R. Gainetdivov (Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia) for his generous assistance with the HPLC studies. The funders had no role in the design, analyses, and interpretation of the submitted study, or decision to publish. Publisher Copyright: {\textcopyright} The Author(s) 2022.",
year = "2022",
month = jul,
doi = "10.1177/02698811221098192",
language = "English",
volume = "36",
pages = "892--902",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "7",
}